Business Insider

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in ...

Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24 Significant improvement in patient-reported asthma ...
Seeking Alpha

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

– Rademikibart demonstrated rapid onset of action with significant improvements in lung function observed at one week and maintained through 24 weeks – – In patients with eosinophilic-driven asthma ...
Nasdaq

Connect Biopharma Reports Positive Clinical Results for Rademikibart in Eosinophilic-Driven Type 2 Asthma Patients

Connect Biopharma Holdings Limited announced promising results from its clinical studies of rademikibart, an investigational anti-IL-4Rα antibody, at the EAACI 2025 Annual Congress. The data show that ...
Nasdaq

Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Business Insider

Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on ...